A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

(2012) Hans-Henrik Parving et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

(2010) Y. Miao et al.   DIABETOLOGIA

Dual RAS Therapy Not on Target, but Fully Alive

(2010) H.J. Lambers Heerspink et al.   NEPHRON CLINICAL PRACTICE

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

(2009) H.-H. Parving et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

(2008) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE